31.1 C
Vientiane
Sunday, May 11, 2025
spot_img
Home Blog Page 506

CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody

SUZHOU, China, March 4, 2025 /PRNewswire/ –CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient has been successfully dosed in the global multicenter Phase I clinical trial of its novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, with no infusion reactions or other adverse events observed.

This trial aims to evaluate the clinical potential of CS2009 in a wide range of advanced solid tumors including, but not limited to, non-small cell lung cancer, hepatocellular carcinoma, gastric adenocarcinoma, endometrial cancer, ovarian cancer, renal cell carcinoma, and cervical cancer, in efforts to advance the development of innovative tumor immunotherapies.

CS2009, an innovative trispecific antibody designed and developed by CStone, combines three clinically validated targets—PD-1, VEGFA, and CTLA-4—and exerts multidimensional anti-tumor effects through synergistic actions. Specifically, anti-PD-1 activity that reverses T cell exhaustion, anti-CTLA-4 activity that promotes T cell activation and proliferation, while anti-VEGFA activity blocks tumor angiogenesis and improves the tumor micro-environment (TME). In the TME, anti-PD-1 and anti-CTLA-4 activities are significantly enhanced by crosslinking with VEGFA. Meanwhile, CS2009 preferentially blocks PD-1 and CTLA-4 on double-positive tumor-infiltrating T cells while minimizing interference with CTLA-4 regulation in peripheral T cells, thus potentially offering enhanced efficacy with lower systemic toxicity.

In preclinical studies, CS2009 demonstrated superior anti-tumor activity compared to potential competitors. By combining CTLA-4 inhibition with PD-1 and VEGFA blockade, CS2009 may further enhance benefits for patients with low or negative PD-L1 expression, who respond poorly to PD-(L)1 therapies. This well positions CS2009 as a next-generation, first- or best-in-class immunotherapy backbone, with the potential to replace current anti-PD-(L)1-based therapies.

Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated, “The initiation of the first-in-human study for CS2009 marks a breakthrough in our clinical development. Our robust preclinical data have confirmed CS2009’s potential across a wide range of solid tumor indications. In in vitro studies, CS2009 demonstrated its ability to effectively and specifically activate tumor-infiltrating T cells, as well as robust synergistic effect with anti-VEGF activity; in immunocompetent mouse models, CS2009 showed stronger anti-tumor effects than both PD-1/CTLA-4 and PD-1/VEGF bispecific antibodies; and in toxicology studies, CS2009 exhibited a safety margin which was greater than the PD-1/CTLA-4 bispecific antibody and comparable to the PD-1/VEGF bispecific antibody. These results give us confidence in CS2009’s clinical potential. We look forward to sharing additional clinical data that will further validate its safety and anti-tumor activity, paving the way for a new era in cancer immunotherapy.”

Dr. Qingmei Shi, Chief Medical Officer of CStone, added, “We are pleased to achieve the first-patient-dosed milestone for CS2009, an innovative trispecific antibody that can potentially offer balanced efficacy and safety while addressing the unmet medical needs in patients with low or negative PD-L1 expression. We expect to see rapid and encouraging progress in this study and are committed to bringing improved treatment options to patients with solid tumors worldwide. We appreciate the exceptional efforts of our clinical team, who managed through the entire process—from submitting the clinical trial application in Australia to dosing the first patient—in two months that overlapped with major holidays in China and Australia. This is another testament to CStone’s outstanding clinical development efficiency and unwavering commitment to serving patients.”

Currently, the multicenter Phase I clinical trial of CS2009 is being conducted in Australia, with plans to expand into China and the United States in the near future.

About CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody)

CS2009 is a trispecific antibody targeting PD-1, VEGFA, and CTLA-4, with the potential to be first- or best-in-class for major tumor types. Its differentiated molecular design combines three clinically validated targets, preferentially invigorating exhausted tumor infiltrating lymphocytes (TILs) while demonstrating VEGF neutralization comparable to existing anti-VEGF antibodies. CS2009 covers a wide range of cancers, including but not limited to non-small cell lung cancer, hepatocellular carcinoma, gastric adenocarcinoma, endometrial cancer, ovarian cancer, renal cell carcinoma, and cervical cancer.

In November 2024, CStone presented preclinical data for CS2009 at the 39th SITC Annual Meeting. These results show that CS2009 exhibits superior anti-tumor activity compared to potential competitors, including PD-1/CTLA-4 bispecific antibodies, PD-1/VEGF bispecific antibodies, and PD-1/CTLA-4 combination therapies.

About CStone 

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications (NDAs) covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit www.cstonepharma.com.   

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

  

Mass production of high-quality, self-standing, large-diameter single-crystal (111) diamond substrates within reach

Development of n-Type Diamonds for Practical Use in Diamond Semiconductors also Making Advances

TOKYO, March 4, 2025 /PRNewswire/ — Orbray has developed production technology for the world’s largest self-standing single-crystal (111) diamond substrates, measuring 20mm square. This achievement marks significant steps in advancing diamond-based quantum devices and power devices. The company aims to commercialize large (111) diamond substrates by 2026 and is also actively working on the development of n-type self-standing diamond substrates, a crucial component for making diamond semiconductor devices mainstream.

Figure: Freestanding 20mm square single-crystal (111) diamond substrate.
Figure: Freestanding 20mm square single-crystal (111) diamond substrate.

Diamond semiconductors are being developed for a wide range of applications due to their exceptional properties. In recent years, there has been significant progress in increasing the size and improving the quality of diamond substrates to meet growing industry demand. High-quality (111) diamond substrates have drawn particular interest in the development of diamond quantum devices that contain nitrogen-vacancy (NV) centers. Additionally, (111) diamond substrates are regarded as essential not only for quantum applications but also for achieving high-performance n-type diamond-based devices, including diamond power devices. However, until now, only small-scale (111) diamond substrates, approximately 3mm square, have been available. (111) diamond crystals were prone to defects known as twin crystals during CVD growth, posing significant challenges to the production of large-diameter and thick single-crystal diamond crystals.

In a September 9, 2021 press release, Orbray Co., Ltd., announced the successful development of a high-quality, 2-inch diameter (100) self-standing diamond substrate using its proprietary efficient step-flow growth method (https://orbray.com/magazine_en/archives/811https://orbray.com/magazine_en/archives/1401). Building on this diamond crystal growth technology and utilizing specially designed sapphire substrates, the company has been advancing the development of a (111) single-crystal diamond self-standing substrate.

This work has culminated in the successful synthesis of a 20mm square (111) single-crystal diamond self-standing substrate without twin defects.

Orbray plans to commercialize this technology by 2026. This advancement is expected to drive progress in the development of diamond semiconductor devices.

Publications related to research results

March 15, 2025, The Japan Society of Applied Physics (JSAP) Spring Meeting: “Large-Diameter (111)-Plane Diamond Free-Standing Crystal Growth”

May 11-15, 2025, International Conference on New Diamond and Nano Carbons: “World-first self-standing (111) heteroepitaxial diamond without twin grown on sapphire substrate”

Orbray Co., Ltd., founded in 1939, specializes in precision jewel parts, small DC motors, and medical equipment, blending cutting-edge technology with craftsmanship. Based in Tokyo, Japan.

Contact

Orbray Co., Ltd., Diamond Division
TEL:+81-3-3919-0101 E-mail:diamond-sales@orbray.com 

Cyber Security Awareness and Human Risk Management Leader SoSafe Launches in Australia

  • By leveraging behavioural science and learning psychology, SoSafe effectively trains users on cybersecurity, with the ultimate goal of strengthening self-defence in a digital and connected world.
  • SoSafe was founded in 2018 and it has quickly become the world’s fastest growing scale-up in cyber security awareness and human risk management.

SYDNEY, March 4, 2025 /PRNewswire/ — SoSafe, a leading provider of security awareness training and human risk management, has today announced its Australia launch, bringing its human-centric approach to cybersecurity to Australian businesses. As Australian firms continue to be battered by cybercrime, this latest expansion is a result of identifying an urgent need for a better approach to mitigating human-related security risks locally.

By using behavioural science and learning psychology, SoSafe helps security leaders make cybersecurity training simple, engaging, and effective — helping people recognise risks faster and take smarter actions effortlessly. It also makes sure security teams can manage their human risk by turning AI into their ally and using data-driven insights to make smarter security decisions. The ultimate goal is to create security cultures among organisations where safe behaviours become second nature – like looking both ways before crossing the street.

According to the Australian Signals Directorate’s Annual Cyber Threat Report, one cybercrime was reported every six minutes on average in FY24. Concerningly, large businesses continue to be impacted by cyberattacks, while an average self-reported cybercrime costs $63,600.

Importantly, human error breaches accounted for a third of total breaches (30%) while 12% of all breaches were caused by phishing. However, such attacks can be avoided by increasing the awareness of cyber threats among employees.

As part of the launch, SoSafe has appointed Jacqueline Jayne as Advocate for Human-Centric Security. A leading expert in the Australian market, Jacqueline has helped numerous companies strengthen their security culture and programs by raising awareness of the human element of cybersecurity and protecting individuals online.

Jacqueline said, “With the pace of cybercriminal innovation outpacing our collective ability to respond, true protection requires more than tools and compliance — it demands a shift in behaviour and a culture of security awareness. The best defence against cyber threats is informed and empowered people. My goal is to make sure Australians have the confidence, context, and knowledge to stay safe online.”

Niklas Hellemann, co-founder and CEO of SoSafe said, “The Australia expansion represents a major milestone for us. Given that we already work with global businesses with operations in Australia, we have deep insights into the challenges they face as cyberattacks become more sophisticated and prevalent. We are committed to providing a powerful solution for Australian businesses that not only engages employees, but actively strengthens cybersecurity at every level of an organisation.

Andrew Rose, Chief Security Officer of SoSafe commented, “Cybersecurity often focuses on technology, while attackers prefer exploiting the human element. SoSafe takes a different approach – combining behavioural science with real-world insights to empower people as the first line of defence. Our platform gives security leaders the visibility and tools to seamlessly integrate awareness into daily operations – not through fear, but with confidence.”

Headquartered in Cologne, Germany, SoSafe supports over 5,500 companies in 37 countries, helping them strengthen the security awareness of thousands of employees and build a sustainable security culture. SoSafe currently has offices in Cologne, Amsterdam, Berlin, Chemnitz, Dublin, London, Paris, Lisbon, Munich, and now, Sydney.

SoSafe has also recently been recognised as a Strong Performer in the inaugural Forrester Wave™: Human Risk Management Solutions, Q3 2024 report, led by Australian based Forrester’s Vice President, Research Director, International Security and Risk Research, Jinan Budge, highlighting its strong market position and strategy.

ENDS

About SoSafe

SoSafe, founded by a team of behavioural scientists and technology experts, is the largest provider of security awareness and human risk management in Europe. SoSafe enables more than 5,500 customers worldwide to effectively minimise cyber risks. With a behavioural psychology approach that focuses on people, SoSafe ensures that safe behaviour becomes innate. 

The company’s aim is to strengthen digital self-defence and sustainably reduce human security risks. To achieve this, they focus on building robust safety cultures and actively involve employees in reducing human safety risks. Based on behaviour-based data and driven by innovative technologies and AI, SoSafe enables security managers to identify, prioritise and effectively reduce human safety risks. The SoSafe team now consists of more than 500 employees in ten locations: Cologne (headquarters), Amsterdam, Berlin, Chemnitz, Dublin, London, Paris, Lisbon, Munich and Sydney.

Website: www.sosafe-awareness.com

MRI Software Announces Proposal to Take Private of Singapore-based Anacle

Proposal will expand MRI’s presence in the Asia-Pacific real estate technology market and create future growth opportunities

SYDNEY, March 4, 2025 /PRNewswire/ — MRI Software, a global leader in real estate solutions and services, announces its proposal to take private of Singapore-based Anacle (8353.HK), a leading provider of digital workplace solutions, energy, facilities, property management, and real estate asset management solutions across Asia.

“This acquisition delivers immediate value to the APAC real estate market and will enable Anacle to focus on future innovations for its property and energy management systems,” said John Ensign, President of MRI Software. “MRI has served the APAC market for 30 years, and this transaction will expand our established footprint in the region, bolster our solution portfolio across Asia, and build on our existing foundation of successful client outcomes.”

Upon completion of the take-private transaction, Anacle will be delisted from the Hong Kong Stock Exchange, which is anticipated to reduce the burden of administrative and compliance requirements for the company. Anacle’s clients will benefit from greater access to MRI’s comprehensive suite of global real estate software solutions in the global markets.

“Since 2006, Anacle has been at the forefront of smart building technology in Singapore,” commented Alex Lau, CEO, Anacle. “With the support of MRI’s extensive resources, services, and expertise, we anticipate that this transaction will bolster our long-term business development and drive scalability for our solutions in the APAC region.”

About MRI Software

MRI Software is a global provider of real estate software applications and hosted solutions. MRI’s purpose-built software helps address the unique operational challenges and financial accounting requirements facing commercial and residential property management operators, property sales and lettings agencies, real estate investment managers and facilities management companies.

MRI serves more than 45,000 organisations across 170 countries. Founded in 1971, MRI is headquartered in Cleveland, Ohio with additional offices across the United States, United Kingdom, Canada, Australia, Hong Kong, Singapore, India and South Africa, as well as an extensive partner channel. For more information, please visit mrisoftware.com/au.

Media and Investor Contact

Audrey Nicoll
Head of APAC Marketing, MRI Software
Audrey.Nicoll@mrisoftware.com

 

 

TECNO Partners with Koç University to Advance Mobile Imaging Aesthetics in Türkiye

BARCELONA, Spain and ISTANBUL, March 4, 2025 /PRNewswire/ — TECNO, an AI-driven technology brand, is teaming up with Koç University in Türkiye, a leading research university located at the intersection of Europe and Asia, to explore the distinctive aesthetic preferences of Turkish consumers in smartphone photography.


This partnership, which extends TECNO’s global research in multi-skin tone imaging technology, aims to enhance its Universal Tone technology and ensures a more customized and culturally attuned imaging experience that aligns with Turkish consumers’ preferences.

Fanyi Zhou, Director of the Image Quality Testing & Assessment Department at TECNO Image Quality Testing lab, stated, “As a distinguished leader in smartphone imaging, we believe this collaboration will enable us to incorporate cutting-edge research insights into our technology. This allows us to customize our camera technology to provide stunning, true-to-life images that celebrate the rich diversity of beauty in Türkiye while staying authentic to individual identities.”

Turkish KOLs experienced TECNO Universal Tone technology
Turkish KOLs experienced TECNO Universal Tone technology

Tailoring Imaging Technology for Turkish consumers

Led by Associate Professor Aykut Coşkun, an internationally renowned design researcher and the director of the KUAR research center, the project merges technology with user-centered design. With a specific focus on understanding Turkish consumers’ aesthetic sensibilities and skin tone preferences, the study utilizing surveys, structured interviews, and field studies, the study will investigate Turkish consumers’ portrait photography habits and preferences, the behaviors and decisions associated with typical photo taking, editing, and posting experience, problems they encountered during this process, and their portrait photography taking experience with TECNO smartphones.

Prof. Coşkun expressed his enthusiasm and commented, “This partnership is an exciting opportunity to bridge academic research with real-world technological innovation. Enabling the exploration and integration of user insights into development efforts in smartphone photography, it has the potential to redefine this process from a user-centered lens.”

Delivering Fully Enhanced and Inclusive Portraits by AI-driven Universal Tone

Results from the studies will play a pivotal role in enhancing TECNO Universal Tone technology. Unveiled in 2023, Universal Tone is a comprehensive multi-skin tone imaging solution that has been continuously evolving and will be integrated into the latest CAMON 40 series.

This technology incorporates three key engines: The Multi-Skin Tone Restoration Engine, the Local Tuning Engine, and the AI-Powered Computational Portrait Engine. The Local-Tuning Engine adapts imaging solutions to diverse environmental factors, including lighting conditions, geomorphological landscapes, and color temperatures, to deliver outputs harmonized with local aesthetics. Meanwhile, the AI-Powered Computational Portrait Engine utilizes TECNO’s self-developed algorithms to create personalized portrait imaging experiences, aligning with cultural and aesthetic preferences unique to each region. This partnership will provide users worldwide with imaging experiences that align with their preferences and local aesthetics.

TECNO’s journey is marked by strategic partnerships with esteemed academic institutions, including the University of Leeds in the UK, Nanyang Technological University in Singapore, and Dar Al-Hekma University in Saudi Arabia. As part of TECNO’s “Glocalization” strategy, these partnerships highlight the brand’s commitment to adapting global innovations to meet the unique demands of local markets. These efforts have been crucial in refining TECNO’s technology, enabling it to accurately depict a spectrum of skin colors and satisfy the aesthetic preferences of various regions.

With a mission to ensure that every consumer of diverse skin tone in emerging markets is accurately represented in our imagery, TECNO has been continuously enhancing imaging technologies and paving the way for a future, where every individual’s beauty is captured with precision and respect.

About TECNO:

TECNO is an innovative, AI-driven technology brand with a presence in over 70 markets across five continents. Committed to transforming the digital experience in global emerging markets, TECNO relentlessly pursues the perfect integration of contemporary aesthetic design with the latest technologies and artificial intelligence. Today, TECNO offers a comprehensive ecosystem of AI-powered products, including smartphones, smart wearables, laptops, tablets, smart gaming devices, the HiOS operating system, and smart home products. Guided by its brand essence of “Stop At Nothing,” TECNO continues to pioneer the adoption of cutting-edge technologies and AI-driven experiences for forward-looking individuals, inspiring them to never stop pursuing their best selves and brightest futures. For more information, please visit TECNO’s official site: www.tecno-mobile.com.

About Koç University:

Founded in 1993 in İstanbul, Koç University is a non-profit research university supported by the resources of the internationally renowned Vehbi Koç Foundation. Since its establishment, Koç University has emerged as a center of global excellence in science and education and is uniquely positioned to explore the overlaps of Medicine, Engineering, Science, Social Sciences and Administrative Sciences to further pursue basic and applied research and attract the best students and faculty members. Through seven colleges and four graduate schools, Koç University offers 22 undergraduate, 44 masters and 30 PhD programs in English. With a student body of 9,000, Koç University has more than 20,000 alumni.

Investor Webinar: Telix Therapeutics Urology Showcase and Expert Forum

MELBOURNE, Australia and INDIANAPOLIS, Ind., March 4, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) invites investors to join a webinar showcasing the Company’s late-stage and next-generation radiotherapeutic candidates in urologic oncology.

In this education session, Telix and global key opinion leaders will provide an overview on the development of its therapeutic candidates in prostate and kidney cancers:

  • Neeraj Agarwal, MD, Professor of Medicine and Presidential Endowed Chair of Cancer Research at Huntsman Cancer Institute in Salt Lake City, UT, will discuss the ProstACT Global Phase 3 trial of TLX591 (177Lu rosopatamab tetraxetan), Telix’s lead radio antibody-drug conjugate (rADC) therapy candidate in prostate cancer.
  • Eric Jonasch, MD, Professor of Medicine in the Department of Genitourinary Medical Oncology at MD Anderson Cancer Center in Houston, TX, will discuss the STARLITE studies of TLX250 (177Lu girentuximab) in combination with immunotherapy, in clear cell renal cell carcinoma.
  • Rodney Hicks, MD, Professor of Medicine at the University of Melbourne and Monash University; Founder, Chair, and Chief Medical Officer at the Melbourne Theranostic Innovation Centre in Australia, will discuss TLX592 (64Cu/225Ac RADmAb®) and the role of targeted alpha therapies in the treatment of prostate cancer.

The webinar will be held on:

EDT: Tuesday March 11, 5.30pm  
AEDT: Wednesday March 12, 8.30am
The event will run for approximately 1.5 hours.

Participants can register for the webcast at the following link: https://edge.media-server.com/mmc/p/39s4k7gw

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). TLX591, TLX592 and TLX250 have not received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com 

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

TCTM Announces the Appointments of Mr. Heng Wang as Chief Executive Officer and Mr. Robert L. Angell as Chief Technology Officer

BEIJING, March 4, 2025 /PRNewswire/ — TCTM Kids IT Education Inc. (NASDAQ: TCTM) (“TCTM” or the “Company“), a leading provider of IT-focused supplementary STEM education services in China, today announced that the board of directors of the Company has approved the re-designation of Mr. Xiaolan Tang as the chief financial officer, and the appointments of Mr. Heng Wang as the chief executive officer and Mr. Robert L. Angell as the chief technology officer of the Company, in each case effective February 28, 2025, as part of the Company’s effort to expand into AI driven technology sector.

Mr. Heng Wang has served as the senior manager at Charles Schwab Corporation, a company focusing on providing brokerage, banking and financial advisory services, from October 2020 to March 2024. Prior to that, Mr. Wang served as a consultant at TD Ameritrade Inc., a stockbroker, from July 2006 to October 2020. Mr. Wang also served as a board member and chair of the nominating and corporate governance committee at Singularity Future Technology Ltd. (NASDAQ: SGLY), an integrated logistics solutions provider, from November 2021 to September 2023. Mr. Wang has over 30 years of experience in the financial industry, specializing in financial technologies, IT strategy and compliance. Mr. Wang received a bachelor’s degree in computer science from Fudan University in 1990 and a master’s degree in computer information science from the New Jersey Institute of Technology in 1991.

Dr. Robert L. Angell currently serves as an advisory board member at the Brain Injury Research Foundation, a foundation focusing on brain injuries, since August 2021. Since January 2021, Dr. Angell has been serving as the chief executive officer and co-founder of EmbraceNFT.io, a non-fungible token platform. In addition, Dr. Angell is also the principal and founder of Applied Quantum Solutions, LLC and Applied Data Sciences, LLC, both data science companies, since September 2020. Dr. Angell has been an advisory board member at Health Data Scientist Association, an organization focusing on health, medical and nursing care related businesses, since April 2019. Since January 2018, Dr. Angell has been serving as the principal and founder of CoMorbus, a public health provider, and a senior data scientist at Cognitech Corporation, a software developer. Previously, Dr. Angell served as an independent advisory board member at Meta Data Limited and NEO Technology Acquisition Corp. Dr. Angell is an expert in healthcare AI, predictive analytics, temporal medicine, and data science. Dr. Angell received a Bachelor of Science degree in Industrial Engineering and a Ph.D. in Biomedical Informatics from the University of Utah.

About TCTM Kids IT Education Inc.

TCTM is a leading provider of IT-focused supplementary STEM education services in China. Through its innovative education platform combining live distance instruction, classroom-based tutoring and online learning modules, TCTM offers IT-focused supplementary STEM education programs, including computer coding and robotics programming courses, etc., targeting students between three and eighteen years of age. Aiming to encourage “code to learn,” TCTM embraces the latest trends in STEM education and technology to develop children’s logical thinking and learning abilities while allowing them to discover their interests and potential.

Safe Harbor Statement

This current report contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. TCTM may also make written or oral forward-looking statements in its reports filed with or furnished to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including any business outlook and statements about TCTM’s beliefs and expectations, are forward-looking statements. Many factors, risks and uncertainties could cause actual results to differ materially from those in the forward-looking statements.

Starlab Advances to Full Development After Successfully Completing Key NASA Milestone

Full development of the Starlab space station begins following the successful completion of the PDR, ensuring a seamless transition of activity from the International Space Station to commercial destinations.

HOUSTON, March 4, 2025 /PRNewswire/ — Starlab Space LLC has cleared a major milestone in its commercial space station development, successfully completing the Preliminary Design Review (PDR) in collaboration with NASA, an important step toward full-scale production.

Rendering of Starlab space station in orbit above Earth
Rendering of Starlab space station in orbit above Earth

The completion of the PDR and an exacting level 1 safety review signify that the station’s architecture, systems and integration plans are ready to advance the project toward certification with the intent to win a future contract for NASA utilization and astronaut activity. This achievement positions the project for the next phase: detailed design and hardware development, leading to a Critical Design Review to confirm the station’s readiness.

“Our successful PDR is a testament to the expertise and dedication of our team,” said Tim Kopra, Starlab CEO. “This milestone confirms that our space station design is technically sound and safe for astronaut crewed operations. Now, with our partners, we shift our focus to the full-scale development of the station, including the manufacturing of critical hardware and software integration.”

“Starlab’s progress underscores our collective commitment to ensuring U.S. leadership in low-Earth orbit with investment and partnership from key allied international organizations and agencies,” said Dylan Taylor, chairman and CEO of Voyager Technologies, the majority shareholder in Starlab’s joint venture. “We are ready to advance human spaceflight, ensure a continuous human presence in LEO, and build a thriving commercial space ecosystem.”

Over the next year, Starlab aims to:

  • Establish a System Integration Lab to serve as the central hub for avionics, computing, sensors and software testing.
  • Procure long lead materials for critical subsystems.
  • Develop a high-fidelity mock-up to support astronaut training and systems testing, with full assembly at NASA’s Johnson Space Center this summer.
  • Advance key life support technologies, including an Advanced Urine Processor.
  • Continue progress on the Optical Link Demo Mission, enhancing future deep-space communication capabilities.
  • Begin construction of Engineering Design Units and Protoflight hardware.

The company is also expanding its facilities in Bremen, Germany, to support assembly, integration and testing operations. Earlier this year, Starlab opened a European subsidiary, Starlab Space GmbH, in Bremen to extend the company’s capabilities and demonstrate its commitment to its international partners.

In addition to the $217.5 million Starlab received from NASA through the Commercial LEO Destinations Phase 1 program and the $15 million awarded by the Texas Space Commission, Starlab is backed by commitments from joint venture partners across the United States, Europe, Japan and Canada. Collaboration with NASA, as evidenced through the completion of the PDR, and investment from global partners positions Starlab to be a leader in the next era of commercial space exploration, driving scientific discovery and technological advancements that can transform humanity.

About Starlab
Starlab Space is a U.S-led, global joint venture among Voyager Technologies, Airbus, Mitsubishi Corporation and MDA Space, with strategic partners including Palantir Technologies, The Ohio State University, Hilton and more. Starlab is developing a next-generation, AI-enabled commercial space station, aiming to ensure continued human presence in Low-Earth Orbit and a seamless transition of microgravity science and research alongside the retirement of the International Space Station. For more information on Starlab, visit www.starlab-space.com